Weight loss studies using GLP1 drug retatrutide leads to reduced pancreatic and lung cancer.
|Congratulations to Sandesh Marathe, PhD and the Makowski lab for their recent publication “Incretin triple agonist retatrutide (LY3437943) alleviates obesity-associated cancer progression“, published in npj Metabolic Health and Disease! This manuscript demonstrates protection from cancer onset and progression with GLP-1 associated medical weight loss using incretin mimetics in several pre-clinical models! Importantly withdrawal of the… Read More